Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: The final results of a phase II trial

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 2, 2011, Pages 361-368

  Katopodis, Ourania ^a   Polyzos, Aris ^a   Kentepozidis, Nikolaos ^a   Giassas, Stylianos ^a   Rovithi, Maria ^a   Bozionelou, Vasiliki ^a   Kalbakis, Kostas ^a   Vamvakas, Lambros ^a   Mavroudis, Dimitris ^a   Georgoulias, Vassilis ^a,b  

^a Hellenic Oncology Research Group HORG   (Greece)

^b University General   (Greece)

Author keywords

Capecitabine; Docetaxel; Pancreas; Phase II trial

Indexed keywords

CAPECITABINE; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROMUSCULAR DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; PANCREAS TUMOR; QUESTIONNAIRE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 79953789546     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1329-6     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin. 59:225-249
2. Saif MW (2007) Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago 8:365-373
3. Poplin E, Feng Y, Berlin J et al (2009) Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic Carcinoma E6201: a trial of the eastern cooperative oncology group. J Clin Oncol 27:3778-3785
4. Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GER-COR and GISCAD phase III trial. J Clin Oncol 23:3509-3516
5. Heinemann V, Quietzsch D, Gieseler FM et al (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952 (Pubitemid 46630743)
6. Herrmann C, Abel U, Stremmel W, Jaeger D, Herrmann T (2007) Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer. Oncology 73:335-339 (Pubitemid 351862025)
7. Boeck S, Wilkowski R, Bruns CJ et al (2007) Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 73:221-227 (Pubitemid 351630054)
8. Cartwright TH, Cohn A, Varkey JA et al (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20:160-164 (Pubitemid 34032607)
9. Boeck S, Hoehler T, Seipelt G et al (2008) Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 19:340-347 (Pubitemid 351201717)
10. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA (2008) Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113:2046-2052
11. Rougier P, Adenis A, Ducreux M et al (2000) A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 36:1016-1025 (Pubitemid 30316427)
12. Pronk LC, Vasey P, Sparreboom A et al (2000) A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 83:22-29 (Pubitemid 30352712)
13. Rosati G, Bilancia D, Germano D et al (2007) Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study. Ann Oncol 18 (Suppl 6):128-132
14. O'Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823 (Pubitemid 34651510)
15. Blaya M LG, Roman E Jr et al (2007) Phase II trial of capecitabine and docetaxel as second line therapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25 (18 S): 15029
16. van Persijn van Meerten EL, Gelderblom H, Bloem JL (2009) RE-CIST revised: implications for the radiologist. A review article on the modified RECIST guideline. European Radiology (in press)
17. Cancer Therapy Evaluation Program (1999) Common Toxicity Criteria. Version 2.0. DCTD, NCI, NIH, DHHS
18. Lutz MP, Van Cutsem E, Wagener T et al (2005) Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 23:9250-9256
19. Kulke MH, Blaszkowsky LS, Ryan DP et al (2007) Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787-4792 (Pubitemid 350086482)
20. National Comprehensive Cancer Network I (2009) Practice Guidelines in Oncology. Pancreatic Adenocarcinoma. v. 1
21. KC Tsavarisn, Skopelitis H, Gouveris P et al (2005) Second line treatment with Oxaliplatin, leucovorin and 5-fluiriuracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs 23:369-375 (Pubitemid 40980360)
22. Gebbia V, Maiello E, Giuliani F, Borsellino N et al (2007) Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncology 18 (Suppl 6):124-127
23. Mitry E, Ducreux M, Ould-Kaci M, Boige V et al (2006) Oxaliplatin combined with 5FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol 30:357-363 (Pubitemid 44020135)
24. Burris HA 3rd, Rivkin S, Reynolds R et al (2005) Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. The Oncologist 10:183-190 (Pubitemid 40463155)
25. Boeck S, Weigang-Kohler K, Fuchs M et al (2007) Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol 18:745-751 (Pubitemid 46523280)
26. Oettle H, Arnold D, Esser M, Huhn D, Riess H (2000) Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anti-cancer Drugs 11:635-638
27. Morizane C, Okusaka T, Furuse J et al (2009) A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 63:313-319
28. Demols A, Peeters M, Polus M et al (2006) Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 94:481-485 (Pubitemid 43289750)
29. Gasent Blesa J, Alberola Candel V, Giner Marco V et al (2009) E. Phase II trial of second-line chemotherapy in metastatic cancer of the pancreas with the combination of oxaliplatin (Ox) and capecitabine (Cp). J Clin Oncol 27 (abstract 15561)
30. Cantore M, Rabbi C, Fiorentini G et al (2004) Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 67:93-97 (Pubitemid 39482675)
31. Mazzer M, Zanon E, Foltran L et al (2009) Second-line pemetrexed-oxaliplatin for advanced pancreatic adenocarcinoma. J Clin Oncol 27 (abstract 15597)
32. Reni M, Pasetto L, Aprile G et al (2006) Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 94:785-791
33. Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. ASCO Meeting Abstracts no 4508
34. Stathopoulos GP, Boulikas T, Vougiouka M, Rigatos SK, Stathopoulos JG (2006) Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep 15:1201-1204
35. Kozuch P, Grossbard ML, Barzdins A et al (2001) Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. The Oncologist 6:488-495 (Pubitemid 33152094)
36. Fine RL, Fogelman DR, Schreibman SM et al (2008) The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 61:167-175 (Pubitemid 47512638)